

Cancer incidence in Gipuzkoa, Spain (1998-2002), and time trends from 1986

Nerea Larrañaga^{a,b} / Cristina Sarasqueta^{b,c} / M. Jesús Michelena^d

^aSubdirección de Salud Pública de Gipuzkoa, Departamento de Sanidad, Gobierno Vasco, Gipuzkoa, Spain; ^bCIBER en Epidemiología y Salud Pública (CIBERESP), Spain; ^cHospital de Donostia, Osakidetza-Servicio Vasco de Salud, Gipuzkoa, Spain; ^dInstituto Oncológico, Gipuzkoa, Spain.

(Incidencia del cáncer en Guipúzcoa [1998-2002] y tendencias desde 1986)

Abstract

Objectives: To determine the cancer incidence in Gipuzkoa (Spain) from 1998 to 2002 and describe time trends since 1986.

Methods: The annual incidence of cancer in Gipuzkoa from 1998 to 2002 was estimated as a rate per 100,000 inhabitants. Incidence trends for the period 1986-2002 were studied for all cancers and for the main cancer sites using Poisson regression and Joinpoint regression for prostate tumours.

Results: On average, one in 3 men and one in 5 women would probably be diagnosed with cancer at some time during their life (0-74 years). Among men, prostate surpassed lung as the most frequent cancer site. Among women, breast cancer represented approximately 30% of all cases of cancer (excluding non-melanoma skin cancers). There was an annual increase in the incidence of cancer of 1.5% (95% CI, 1.1-1.8) in men and 0.9% (95% CI, 0.5-1.3) in women. The incidence of prostate cancer in men increased over the study period, and especially between 1996 and 1999, with an annual increase of 34.7% (95% CI, 5.9-71.5). The incidence of lung cancer in women presented an annual increase of 5.2% (95% CI, 3.4-7.1). In contrast, the incidence of stomach cancer decreased during the study period.

Conclusions: Cancer incidence in Gipuzkoa increased during the study period. This increase was particularly marked in lung cancer and skin melanoma, for which preventive strategies are fundamental.

Key words: Cancer. Neoplasm. Incidence. Trends.

Resumen

Objetivos: Conocer la incidencia de cáncer en Guipúzcoa entre 1998 y 2002, y su evolución desde 1986.

Métodos: Se realizan estimaciones de incidencia anual del cáncer en el período 1998-2002, para Guipúzcoa, en tasas por 100.000 habitantes. Se analiza su evolución entre 1986 y 2002 en el conjunto de localizaciones y en las más frecuentes, mediante el modelo de regresión de Poisson y el modelo de regresión Joinpoint en tumores de próstata.

Resultados: Uno de cada 3 varones y una de cada 5 mujeres de Guipúzcoa tienen la probabilidad de desarrollar cáncer a lo largo de su vida (rango, 0-74 años). En varones, el cáncer de próstata ocupa el primer lugar, seguido del cáncer de pulmón. En mujeres, el cáncer de mama representa cerca del 30% del total (excluido el de piel no melanoma). Se observa un incremento anual de incidencia en varones del 1,5% (intervalo de confianza [IC] del 95%, 1,1-1,8) y del 0,9% (IC del 95%, 0,5-1,3) en mujeres. Aumentan los tumores de próstata en varones, especialmente en el período 1996-1999 en un 34,7% anual (IC del 95%, 5,9-71,5), y el cáncer de pulmón en las mujeres en un 5,2% anual (IC del 95%, 3,4-7,1), mientras que los tumores de estómago descienden en el período de estudio.

Conclusiones: La incidencia de cáncer en Guipúzcoa aumenta en el período de estudio; destacan los tumores de pulmón y melanoma cutáneo, donde las estrategias preventivas desempeñan un papel primordial.

Palabras clave: Cáncer. Tumores malignos. Incidencia. Tendencia.

Correspondence: Nerea Larrañaga.
Subdirección de Salud Pública de Guipúzcoa.
Avda. de Navarra, 4. 20013 Donostia. España.
E-mail: epidem3-san@ej-gv.es

Received: April 2, 2007.
Accepted: September 27, 2007.

Introduction

Cancer is one of the most important public health problems in our community, as in other regions. It has enormous health and socio-economic implications and constitutes the most frequent cause of premature and avoidable death. In Gipuzkoa 1,600 people die of cancer every year and 3,000 new neoplasms are diagnosed. Cancer is identified as one of the priority health problems within the scope of the Euskadi Health Plan¹.

It is also known that the incidence of different types of cancer varies from one country to another, depending on etiological factors and also on the availability of efficient methods of prevention, diagnosis and treatment². Obtaining the most accurate data possible relating to these aspects therefore constitutes the first step towards appropriately planning prevention programs and assigning the health resources required to achieve more efficient results, in accordance with the scientific evidence available at any given time.

Population based cancer registry is an essential part of any rational program of cancer control³. Its primary function is to keep a file or register of all cases occurring in a defined population. The registry analyses and interprets such data periodically and provides information on the epidemiology of cancer. The value of a cancer registry depends on the quality of its data and the extent to which they are used in research and health service planning⁴. Quality control carried out at the local level for each of the registries is undoubtedly reinforced by international collaboration⁵⁻⁹.

The aim of this study was to provide insights into the epidemiology of invasive cancer in Gipuzkoa by analyzing population based incidence and time trends, with special emphasis on sex and site-specific changes over time.

Methods

The study of cancer incidence included all invasive neoplasms (except epidermoid and basocellular skin tumours) diagnosed in residents of Gipuzkoa during the period 1998-2002. According to the 2001 census, this population numbered 673,563 (330,454 men and 343,109 women). The period was extended to 1986-2002 to analyse time trends. Population estimates in the denominator for calculation of incidence rates were obtained from the Basque Institute of Statistics.

The main sources of information for the population cancer registry were the 2 hospital cancer registries available in Gipuzkoa (Hospital Donostia and Instituto Oncológico). These institutions actively search for cases in the Pathological Anatomy (biopsies, cytologies and autopsies) and Clinical Documentation (hospital discharges) services, and also in other services. Similar data were actively collected and compiled at other public, concerted and private hospitals in Gipuzkoa. Death certificates (DC) were also consulted. Finally, cases were regularly obtained from the cancer registries of neighbouring communities.

The use of multiple sources makes it possible for the same case to be received more than once, so data were cross-checked in order to avoid duplication. Duplication, processing and concordance control were duly carried

out in all cases identified as being new to the registry. The automatic quality control program IARC-CHECK¹⁰ was used as the final tool for controlling the quality of the data processed.

The variables used in the study were: *a)* personal data: gender and age; *b)* tumour data: anatomical site of the primary tumour and its morphology, codified according to the 2nd edition of the International Classification of Diseases for Oncology (ICD-O-II)¹¹, and date of diagnosis or incidence, and *c)* quality indicators: diagnostic basis, indicating the most valid basis for diagnosis and grouped into 2 categories, non-microscopic (clinical, clinical research, surgery and tumour markers) and microscopic (cytology, histology and autopsy). Cases whose only source of information was the DC were assigned to a separate category.

Data analysis

The average annual incidence of cancer in Gipuzkoa for the period 1998-2002 is presented for all sites together, and also for specific sites, and expressed in rates per 100,000 persons at risk per year. Crude, age-specific and age-standardized incidence rates were calculated by gender, using the direct method and adjusted with European and World population data³. Furthermore, cumulative incidence rates were calculated for each site and gender, from birth to 65 and 75 years of age.

The cancer incidence trend for the period 1986-2002 was studied for all tumours and the most frequent sites. The general trend was quantified by applying the Poisson regression¹², after adjusting for age, with separate models for men and women. In this model, a linear trend was assumed for the logarithm of the rates. Goodness of fit was assessed by *deviance* and its degrees of freedom. The significance level was set at 0.05. In the case of prostate cancer, the Poisson model did not fit correlated as a result of changes in the trend during the study period. This was related to the generalised use of prostatic specific antigen (PSA) during the final 5-year period. A joinpoint regression model was therefore used to analyse the time-related trends for these tumours. This made it possible to estimate annual percentage change (APC) and to identify trend inflexion points when they were present¹³. For data analysis, we used version 9.1 of the SAS statistical package¹⁴ and version 3.0 of the Joinpoint Regression program¹⁵.

Results

The number of neoplasms registered in Gipuzkoa between the years 1998 and 2002 was 16,329, of which

9,991 were diagnosed in men and 6,338 in women. This meant a crude annual incidence rate, for the period 1998-2002, of 604.2 per 100,000 male inhabitants and 369.1 per 100,000 females.

During this 5-year period, 61% of the cancers registered in men and 54% of those in women were diagnosed in people over 65 years of age, with 26% and 32%, respectively, being diagnosed in men and women over 75 years of age. The cumulative rates for ages 0 to 64 were found to be 18.8% in men and 13.3% in women and those for ages 0 to 74 were, 42.0% in men and 21.3% in women.

The incidence of cancer increased with age; rates were very similar for men and women until 20 years of age, but between 20 and 45 rates in females were higher than those in males. However, from this age on, there was a gradual increase in the incidence for both groups, with a more marked increase for men (fig. 1).

The mean age at diagnosis for the whole period was 65.5, with it greater for men (66.1 years) than for women (64.8 years). This was mainly due to the fact that average age at the appearance of breast tumours (60.3 years), the most frequent cancer in women, was lower than that of prostate tumours (71.4 years), the most common type of cancer in men. However, for the most frequent tumours common to both sexes, age at appearance was greater in women. This was the case of

tumours located in the stomach (men 68.6, women 73.3), colon-rectum (men 68.3 and women 70.4), bladder (men 67.1, women 71.8) and oral cavity and pharynx (men 60.1 and women 63.0).

During the study period, the prostate (22.9%) was the most frequently affected site in men, followed by the tracheal-bronchial-lung (C33-C34: 14.6%) and colon-rectum (C18-C20: 12.6%) (table 1). Breast cancer (27.9%) was the most frequent neoplasm in women, followed by colorectal cancer (C18-C20: 13.4%) and cancer of the uterus (C53-C55: 8.7%) (table 2).

In general, neoplasms were more frequent in men than in women for all sites except thyroids and skin melanomas. The age-standardized rate ratio between men and women for all sites was 2.7, and the sites with the highest rate ratios were the larynx (19.1), oesophagus (7.2), tracheal-bronchial-lung (7.2), urinary bladder (6.9) and lip-oral cavity and pharynx (4.9).

Between the years 1986 and 2002, the incidence of cancer in Gipuzkoa underwent an annual increase of 1.46% (95% confidence interval CI, 1.14-1.77) in men and 0.91% (95% CI, 0.53-1.30) in women. Trends for the most frequent sites are shown in table 3. In men, the tumour site with the greatest increase during the study period was the prostate. This increase was not linear. It is possible to distinguish 3 well-differentiated periods: 1986-1996, with an APC of 2.9% (95% CI, 0.1-5.8); 1996-1999, with an annual increase of 34.7% (95%

Figure 1. Cancer incidence in Gipuzkoa (1998-2002) by age group and sex.




Table 1. Cancer incidence in males in Gipuzkoa (1998-2002)

ICD-O-II	Topography	Cases		Rate per 100,000			Cumulative rate (%)	
		n	Percentage	Crude	ASR(E)	ASR(W)	0-64	0-74
C00	Lip	56	0.56	3.39	2.82	1.92	0.26	0.09
C01-C02	Tongue	96	0.96	5.81	5.17	3.72	0.47	0.26
C03-C06	Mouth	92	0.92	5.56	5.00	3.77	0.46	0.27
C07-C08	Salivary glands	24	0.24	1.45	1.28	0.91	0.07	0.06
C09	Tonsils	33	0.33	2.00	1.82	1.35	0.16	0.12
C10	Other oropharynx	34	0.34	2.06	1.90	1.38	0.16	0.12
C11	Nasopharynx	27	0.27	1.63	1.49	1.13	0.14	0.10
C12-C13	Hypopharynx	93	0.93	5.62	5.12	3.75	0.43	0.31
C14	Unspecified pharynx	47	0.47	2.84	2.59	1.94	0.20	0.15
C15	Oesophagus	220	2.19	13.31	11.77	8.23	0.93	0.58
C16	Stomach	543	5.41	32.84	27.54	18.29	2.22	0.88
C17	Intestine	11	0.11	0.67	0.58	0.41	0.04	0.03
C18	Colon	761	7.59	46.02	38.21	25.32	3.03	1.15
C19-C20	Rectum	495	4.93	29.94	25.26	17.09	2.14	0.93
C21	Anus	10	0.10	0.61	0.51	0.37	0.03	0.02
C22	Liver	267	2.66	16.15	13.61	9.43	1.23	0.46
C23-C24	Gall bladder and bile duct	75	0.75	4.54	3.78	2.34	0.22	0.08
C25	Pancreas	222	2.21	13.43	11.46	7.92	0.95	0.46
C30-C31	Nose, sinuses and ear	30	0.30	1.81	1.55	1.12	0.14	0.07
C32	Larynx	343	3.42	20.74	18.38	13.33	1.63	0.96
C33-C34	Trachea, bronchus and lung	1,461	14.56	88.36	74.97	51.54	6.25	2.91
C37-C38	Other thoracic organs	12	0.12	0.73	0.61	0.47	0.06	0.03
C40-C41	Bone	27	0.27	1.63	1.80	1.91	0.15	0.13
C43	Skin melanoma	133	1.33	8.04	7.15	5.41	0.59	0.38
C45	Mesothelioma	20	0.20	1.21	1.02	0.69	0.09	0.04
C46	Kaposi sarcoma	14	0.14	0.85	0.74	0.54	0.05	0.05
C47+C49	Connective and soft tissues	53	0.53	3.21	2.87	2.20	0.21	0.15
C50	Breast	26	0.26	1.57	1.36	0.89	0.10	0.05
C60	Penis	23	0.23	1.39	1.18	0.78	0.10	0.03
C61	Prostate	2,293	22.86	138.67	111.68	72.20	9.30	2.43
C62	Testicle	61	0.61	3.69	3.23	3.13	0.23	0.23
C63	Other male genital organs	3	0.03	0.18	0.16	0.10	0.01	0.00
C64	Kidney	323	3.22	19.53	16.82	11.68	1.35	0.73
C65	Pelvis renal	34	0.34	2.06	1.69	1.16	0.15	0.05
C66	Ureter	14	0.14	0.85	0.67	0.45	0.05	0.02
C67	Bladder	766	7.64	46.32	39.11	26.45	3.02	1.43
C68	Other urinary organs	1	0.01	0.06	0.05	0.04	0.01	0.00
C69	Eye	9	0.09	0.54	0.53	0.47	0.05	0.03
C70-C72	Brain, nervous system	177	1.76	10.70	9.76	7.62	0.82	0.56
C73	Thyroid	47	0.47	2.84	2.55	2.18	0.20	0.16
C74	Adrenal gland	8	0.08	0.48	0.40	0.30	0.03	0.02
C75	Other endocrine glands	2	0.02	0.12	0.10	0.12	0.01	0.01
C81	Hodgkin lymphoma	69	0.69	4.17	3.93	3.80	0.30	0.27
C82-85, C96	Non-Hodgkin lymphoma	289	2.88	17.48	15.43	11.62	1.24	0.76
C88	Immunoproliferative diseases	4	0.04	0.24	0.18	0.12	0.02	0.00
C90	Multiple myeloma	89	0.89	5.38	4.42	2.96	0.35	0.14
C91	Lymphoid leukaemia	97	0.97	5.87	5.50	4.49	0.40	0.22
C92-C94	Myeloid leukemia	43	0.43	2.60	2.25	1.69	0.17	0.09
C95	Unspecified leukemia	58	0.58	3.51	2.97	2.12	0.24	0.10
O&U	Other and poorly defined	396	3.95	23.95	20.15	13.42	1.49	0.63
C00-O&U	All sites	10,031	100.00	606.63	513.10	354.26	41.96	18.75

ASR(E): age-standardized rates (European population); ASR(W): age-standardized rates (world population).

Table 2. Cancer incidence in women Gipuzkoa (1998-2002)

ICD-O-II	Topography	Cases		Rate per 100,000			Cumulative rates (%)	
		n	Percentage	Crude	ASR(E)	ASR(W)	0-64	0-74
C00	Lip	12	0.19	0.70	0.38	0.25	0.04	0.00
C01-C02	Tongue	34	0.53	1.98	1.54	1.17	0.15	0.06
C03-C06	Mouth	29	0.46	1.69	1.15	0.80	0.09	0.05
C07-C08	Salivary glands	19	0.30	1.11	0.88	0.71	0.07	0.05
C09	Tonsils	5	0.08	0.29	0.25	0.21	0.02	0.02
C10	Other oropharynx	1	0.02	0.06	0.06	0.04	0.00	0.00
C11	Nasopharynx	7	0.11	0.41	0.35	0.26	0.03	0.02
C12-C13	Hypopharynx	5	0.08	0.29	0.27	0.21	0.02	0.02
C14	Unspecified pharynx	12	0.19	0.70	0.61	0.44	0.05	0.04
C15	Oesophagus	44	0.69	2.56	1.70	1.14	0.10	0.07
C16	Stomach	267	4.19	15.55	9.34	6.19	0.70	0.27
C17	Intestine	9	0.14	0.52	0.33	0.22	0.03	0.01
C18	Colon	585	9.19	34.07	21.89	14.71	1.67	0.79
C19-C20	Rectum	263	4.13	15.32	10.35	6.98	0.82	0.40
C21	Anus	15	0.24	0.87	0.61	0.41	0.04	0.02
C22	Liver	111	1.74	6.47	3.72	2.43	0.29	0.08
C23-C24	Gall bladder and bile duct	124	1.95	7.22	4.33	2.83	0.32	0.13
C25	Pancreas	207	3.25	12.06	7.33	4.82	0.55	0.23
C30-C31	Nose, sinuses and ear	9	0.14	0.52	0.46	0.42	0.03	0.03
C32	Larynx	19	0.30	1.11	0.91	0.70	0.08	0.05
C33-C34	Trachea, bronchus and lung	232	3.64	13.51	9.95	7.15	0.77	0.47
C37-C38	Other thoracic organs	8	0.13	0.47	0.42	0.39	0.03	0.02
C40-C41	Bone	15	0.24	0.87	0.77	0.67	0.05	0.05
C43	Skin melanoma	209	3.28	12.17	10.06	7.90	0.79	0.60
C45	Mesothelioma	9	0.14	0.52	0.41	0.31	0.04	0.02
C46	Kaposi sarcoma	5	0.08	0.29	0.15	0.09	0.01	0.00
C47+C49	Connective and soft tissues	43	0.68	2.51	2.19	2.01	0.17	0.12
C50	Breast	1,778	27.92	103.56	84.81	62.91	6.75	5.05
C51	Vulva	53	0.83	3.09	1.79	1.16	0.10	0.06
C52	Vagina	8	0.13	0.47	0.41	0.33	0.03	0.02
C53	Cervix uteri	120	1.88	6.99	5.92	4.54	0.49	0.34
C54	Corpus uteri	410	6.44	23.88	18.32	12.95	1.60	0.93
C55	Uterus unspecified	20	0.31	1.17	0.77	0.52	0.04	0.04
C56	Ovary	232	3.64	13.51	10.87	8.28	0.88	0.62
C57	Other female genital organs	9	0.14	0.52	0.40	0.28	0.03	0.02
C64	Kidney	136	2.14	7.92	5.67	4.17	0.44	0.23
C65	Renal pelvis	5	0.08	0.29	0.17	0.11	0.02	0.00
C66	Ureter	3	0.05	0.18	0.15	0.12	0.02	0.01
C67	Bladder	157	2.47	9.14	5.65	3.81	0.42	0.19
C69	Eye	12	0.19	0.70	0.58	0.50	0.04	0.03
C70-C72	Brain, nervous system	167	2.62	9.73	7.04	5.30	0.52	0.34
C73	Thyroids	127	1.99	7.40	6.54	5.41	0.53	0.42
C74	Adrenal gland	12	0.19	0.70	0.67	0.62	0.04	0.04
C81	Hodgkin lymphoma	44	0.69	2.56	2.46	2.44	0.00	0.00
C82-85, C96	Non-Hodgkin lymphoma	260	4.08	15.14	10.90	8.16	0.19	0.17
C88	Immunoproliferative disease	1	0.02	0.06	0.02	0.01	0.87	0.50
C90	Multiple myeloma	84	1.32	4.89	3.11	2.07	0.26	0.10
C91	Lymphoid leukemia	54	0.85	3.15	2.45	2.10	0.21	0.11
C92-C94	Myeloid leukemia	23	0.36	1.34	1.03	0.85	0.08	0.05
C95	Unspecified leukemia	57	0.89	3.32	2.33	1.82	0.16	0.10
O&U	Other land poorly defined	299	4.69	17.42	9.73	6.24	0.59	0.26
C00-O&U	All sites	6,369	100.00	370.96	272.16	198.14	21.27	13.26

ASR(E): age-standardized rates (European population); ASR(W): age-standardized rates (world population).

Table 3. Cancer incidence in Gipuzkoa (1986-2002): rates (per 100,000) and time trends (Poisson regression)

Males					
ICD-O-II	Topography	ASR(W) 1986 (95%CI)	ASR(W) 2002 (95%CI)	APC (95%CI)	Deviance
C00-C14	Oropharynx	27.5 (22.28 to 32.64)	17.2 (13.55 to 20.83)	-2.1 (-2.99 to -1.28)	0.8447
C15	Oesophagus	10.5 (7.30 to 13.67)	9.0 (6.40 to 11.66)	-2.5 (-3.84 to -1.08)	1.0450
C16	Stomach	28.1 (22.92 to 33.34)	16.2 (12.86 to 19.45)	-2.8 (-3.68 to -1.83)	1.0700
C18-C20	Colon-rectum	29.8 (24.43 to 35.20)	46.2 (40.55 to 51.92)	2.6 (1.73 to 3.41)	1.3294
C22	Liver	7.0 (4.35 to 9.60)	9.1 (6.50 to 11.66)	1.3 (-0.24 to 2.79)	1.0190
C23-C24	Gall bladder and bile duct	0.6 (-0.09 to 1.29)	2.3 (1.03 to 3.49)	-0.7 (-3.32 to 2.00)	1.1486
C25	Pancreas	6.0 (3.56 to 8.34)	9.4 (6.75 to 12.09)	0.4 (-1.30 to 2.21)	1.1653
C32	Larynx	20.8 (16.33 to 25.21)	14.3 (11.01 to 17.63)	-1.8 (-3.02 to -0.63)	1.1370
C33-C34	Trachea, bronchus, lung	49.0 (42.12 to 55.86)	52.2 (46.06 to 58.33)	0.4 (-0.28 to 1.02)	1.1139
C43	Skin melanoma	2.1 (0.63 to 3.57)	5.3 (3.25 to 7.35)	4.6 (2.07 to 7.20)	1.1078
C61	Prostate	16.4 (12.41 to 20.33)	78.3 (71.15 to 85.42)		2.8999 ^a
C67	Bladder	23.0 (18.32 to 27.67)	25.0 (20.84 to 29.20)	0.2 (-0.72 to 1.09)	1.1416
C64-C66	Kidney and ureter	7.7 (4.80 to 10.62)	13.2 (10.09 to 16.23)	2.9 (1.48 to 4.23)	1.0207
C73	Thyroids	1.0 (-0.11 to 1.54)	2.4 (0.89 to 3.87)	5.6 (1.76 to 9.59)	0.9370
C91-C95	Leukemias	8.7 (5.52 to 11.93)	8.4 (5.08 to 11.67)	-0.4 (-2.02 to 1.33)	1.0614
O&U	Other and poorly defined	18.9 (14.56 to 23.19)	12.0 (9.08 to 14.84)	-2.2 (-3.32 to -1.09)	1.0549
Females					
ICD-O-II	Topography	ASR(w) 1986 (95%CI)	ASR(w) 2002 (95%CI)	ASR(w) (95%CI)	Deviance
C00-C14	Oropharynx	2.4 (1.07 to 3.84)	3.6 (1.61 to 5.65)	2.5 (0.13 to 4.93)	1.0525
C15	Oesophagus	0.6 (-0.03 to 1.32)	1.4 (0.39 to 2.45)	3.5 (-0.64 to 7.76)	0.9194
C16	Stomach	10.4 (7.67 to 13.23)	6.0 (4 to 8.04)	-4.4 (-5.67 to -3.10)	1.0881
C18-C20	Colon-rectum	14.7 (11.46 to 17.83)	20.4 (16.83 to 23.93)	1.5 (0.64 to 2.37)	1.0187
C22	Liver	1.8 (0.65 to 3.03)	3.0 (1.56 to 4.48)	3.2 (0.89 to 5.57)	0.8463
C23-C24	Gall bladder and bile duct	4.8 (2.99 to 6.62)	1.98 (1.01 to 2.94)	2.3 (-4.09 to -0.38)	0.9046
C25	Pancreas	3.1 (1.81 to 4.39)	4.8 (3.12 to 6.47)	1.0 (-0.72 to 2.81)	1.0568
C33-C34	Trachea, bronchus, lung	4.0 (2.24 to 5.79)	7.9 (5.47 to 10.25)	5.2 (3.36 to 7.05)	0.9540
C43	Skin melanoma	3.1 (1.49 to 4.81)	7.5 (4.81 to 10.19)	4.6 (2.59 to 6.67)	1.1709
C50	Breast	44.8 (38.39 to 51.13)	57.5 (50.84 to 64.06)	1.5 (0.79 to 2.24)	1.5815
C53	Cervix	3.1 (1.47 to 4.78)	3.6 (1.97 to 5.24)	-0.5 (-2.60 to 1.60)	1.0527
C54	Uterine corpus	9.7 (6.90 to 12.54)	12.1 (9.17 to 15.09)	2.8 (1.54 to 4.01)	0.9829
C56	Ovary	9.1 (6.22 to 11.97)	7.2 (4.49 to 9.88)	-1.0 (-2.49 to 0.45)	1.0459
C67	Bladder	2.5 (1.23 to 3.84)	3.4 (2.06 to 4.81)	-0.5 (-1.44 to 2.45)	0.9718
C64-C66	Kidney and ureter	1.9 (0.68 to 3.20)	4.5 (2.29 to 6.73)	1.6 (-0.13 to 3.44)	0.7795
C73	Thyroids	2.2 (0.76 to 3.73)	8.0 (5.24 to 10.69)	4.0 (1.67 to 6.46)	1.1146
C91-C95	Leukemias	3.4 (1.32 to 5.50)	5.0 (2.20 to 7.72)	0.2 (-1.89 to 2.23)	1.1206
O&U	Other and poorly defined	14.2 (11.09 to 17.30)	4.7 (3.10 to 6.39)	-3.9 (-5.25 to -2.60)	1.1325


^aBad fit.

ASR(W): age-standardized rates (world population); APC: annual percentage change; CI: confidence interval.

CI, 5.9-71.5); and 1999-2002, in which no significant changes were observed (fig. 2). After prostate cancer, the tumours with the greatest APC in men were: thyroid (5.6%), skin melanoma (4.6%), kidney (2.8%) and colon-rectum (2.6%) cancer. Significant decreases were observed in stomach (2.8%), oesophagus (2.5%) and lip-oral cavity-pharynx (2.1%) cancer. No significant changes were observed in the incidence of tracheal-bronchial-lung and bladder urinary tumours. In women, the greatest annual increase occurred in tracheal-bronchial-lung tumours (5.2%), followed by skin melanoma

(4.6%) and thyroid (4.0%) cancer. Significant decreases were observed in stomach tumours (4.4%) and in gallbladder and bile duct tumours (2.3%). No significant changes were observed in tumours of the cervix, ovary and urinary bladder.

The quality indicators used showed a high degree of exhaustiveness and highlighted the good quality of the data compiled. Over the whole period, there were only 5 cases in which the age and date of birth were unknown at the moment of diagnosis, and none in the last five-year period. The percentage of cases with his-

Figure 2. Age-standardized incidence trends of prostate cancer in Gipuzkoa (1986-2002).

APC: annual percent change; CI: confidence interval.

tological verification was almost 90% for the last five-year period, while during the same period the proportion of cases with unknown or poorly defined primary sites was less than 5%, with an annual decrease of 2.2% in men and 3.9% in women over the study period (table 3). Finally, cases in which the only source of data was the death certificate (DCO) accounted for less than 2.5% of the total in the last few years.

Discussion

The average annual frequency of appearance of new cases of cancer in Gipuzkoa between 1998 and 2002 was 607/100,000 for men and 371/100,000 for women, with a standardized man/woman rate ratio of 2.7 and an average age at diagnosis of 66 years for men and 64 for women.

Data published from the Spanish cancer registries¹⁶⁻¹⁸ shows a north-south gradient in men, with higher incidence rates in the north of Spain, in contrast to women with similar rates in Navarra, the Basque Country and Tarragona, and somewhat lower rates in Granada and Zaragoza¹⁹. In periods prior to 1998, incidence rates for cancer in women resident in Gipuzkoa, as for those for women from other regions of Spain, were amongst the lowest in Europe, while those for men were similar to the European average.

The pattern of cancer in men from Gipuzkoa for the last 5-year period studied shows a high incidence of tobacco and alcohol related tumours (lip, oral cavity, pharynx, larynx, oesophagus and lung). Similar rates were observed in previous periods for this region and also for the whole of Spain²⁰. Lung cancer, which was the most frequent neoplasm in males in previous periods, descended to second place, mainly due to the significant increase in prostate tumours. In women, incidence data for the five-year period 1998-2002 show a similar pattern to those of previous periods, with a gradual increase in the rates of the most frequent tumours: breast and colon-rectum tumours, and also in cancers of the uterus. Malignant breast cancers represented 28% of all cancers (excluding non-melanoma skin cancer) and followed the same upward trend observed in other regions of Spain and countries worldwide²¹⁻²³.

In general, a progressive increase in the number of cancer cases was observed during the study period in both men and women. The overall annual increases in the incidence of cancer were 1.5% in men and 0.9% in women. This overall increase in the detection of tumours corresponds to general trends for the most frequent tumours in both men and women. The exceptions to the rule were stomach tumours, which decreased in both sexes, and tumours of the oral cavity and pharynx and oesophagus, which decreased in men.

In men, the great increase observed in prostate cancer, with an annual increase of 2.9% in the period 1986-

1996, and a very sharp annual increase (34.7%) between 1996 and 1999, reflects the increase in diagnosis related to the widespread use of the PSA test. Registered cases of prostate cancer have been on the increase in France since 1985 and in Spain since 1990²⁴. Nevertheless, in the data presented here, the observed increase was 100% in 3 years, while increases in detection associated with the use of PSA in other countries, in earlier periods, were more gradual^{25,26}. On the other hand, the incidence of lung cancer stabilized, but the decrease described in some other European countries and in the USA was not observed^{27,28}. In some European countries, the incidence of lung cancer in men has decreased since the 1980's, while in southern Europe it continued to increase until the 1990's, with a pattern reflecting the epidemic of tobacco smoking affecting certain regions²⁹. The number of male smokers in some northern European countries began to descend in the 1960's. Nevertheless, in some southern European countries, including Spain, this decrease in male tobacco consumption did not begin until the 1980's³⁰.

In women, although the increases in breast and colon-rectum cancers were greater, in absolute numbers, than those observed for other tumours, the greatest percentage increases were observed for tumours such as lung cancer (5.2% annually). Although the incidence rates of these tumours are still much lower than for men, they are now increasing, as previously occurred in other western nations^{25,27,31}. Tobacco consumption by Spanish women increased rapidly from 1970 onwards and continued to increase until the 1990's³¹. This implied a lag of 20-40 years compared to the experience of women in other western countries and this will also be reflected in the evolution of the incidence of tobacco-related cancers³².

The incidence of melanoma in Gipuzkoa showed an annual increase of 4.6% in both men and women. The incidence of these tumours in Europe has been rising steadily, albeit with differences between countries³³⁻³⁵, though a deceleration in the general trend has been observed in northern Europe³⁶. This general increase has been associated with exposure to ultraviolet radiation in combination with endogenous factors such as skin type and genetic predisposition³⁷. Finally, the increase in the incidence of thyroid cancer, particularly in women (4%), has also been described by other authors, as has a decline in mortality rates^{38,39}. This indicates that the observed increase may be due to improved diagnosis and to the identification of a greater number of small, well-differentiated, tumours. Exposure to radiation and other substances that affect the thyroid function are amongst the etiological factors⁴⁰, thus this type of tumour showed a greater incidence in areas of endemic goitre.

For the last period studied, the quality indicators of the cancer register support both the validity and the ex-

haustiveness of the cancer registry, confirming the quality of the data presented. In addition, the decrease observed in the number of tumours with poorly defined sites was clearly related to improvements in the quality of diagnostic data. An age-period-cohort analysis for specific sites would provide more detailed data about factors that could possibly explain the increase in the incidence of cancer. In Spain, pronounced cohort effects have been described for lung⁴¹ and breast²¹ cancer, amongst others, indicating respective changes in the prevalence of risk factors such as tobacco and reproductive aspects, in specific birth-defined cohorts. In the case of prostate cancer, the period considered and the generalized use of PSA seems to have had a greater effect on the changes observed, which affected all age groups. Even so, significant cohort effects have also been described suggesting the influence of etiological factors⁴².

In conclusion, the study data reflect an important rise in the incidence of neoplasms in Gipuzkoa in most sites, and most notably in those associated with preventable risk factors, as is the case of lung tumours in women and skin melanoma in both sexes.

Acknowledgements

We would like to thank the people responsible for and workers of the departments who supplied the data to the cancer registry. In particular, we would like to thank the people responsible for actively gathering, codifying and registering the data in the 3 registries: Mercedes Laviñeta, Conchi Mugarza, M. Carmen San Sebastián and Marian Ugarte. Lastly, thanks go to Mikel Basterretxea for his comments during the editing of the present manuscript.

Bibliography

1. Departamento de Sanidad del Gobierno Vasco. Políticas de salud para Euskadi: Plan de salud 2002-2010. 1.ª ed. Vitoria-Gasteiz: Servicio central de Publicaciones del Gobierno Vasco; 2002.
2. Lagiou P, Adammi HO. Burden of cancer. In: Adami HO, Hunter D, Trichopoulos D, editors. Textbook of cancer epidemiology. New York: Oxford University Press; 2002. p. 3-28.
3. Jensen OM, Parkin DM, MacLennan R, Muir CS, Skeet RG. Registros de cáncer. Principios y métodos. Lyon: IARC; 1995. Publicaciones científicas n.º 95.
4. Parkin DM, Chen VW, Ferlay J, Galceran J, Storm HH, Whelan SL. Comparabilidad y control de calidad en los registros de cáncer. Lyon: IARC; 1995. Informe Técnico n.º 19.
5. Izarzugaza JM, Juan D, Pons C, Ranea JA, Valencia A, Pazos F. TSEMA: interactive prediction of protein pairings between interacting families. Nucl Acids Res. 2006;34:315W-9W.
6. Izarzugaza MI, Steliarova-Foucher E, Martos MC, Zivkovic S. Non-Hodgkin's lymphoma incidence and survival in European children and adolescents (1978-1997): report from the Automated Childhood Cancer Information System project. Eur J Cancer. 2006;42:2050-63.

7. Montanaro F, Bray F, Gennaro V, Merler E, Tyczynski JE, Parkin DM, et al. Pleural mesothelioma incidence in Europe: evidence of some deceleration in the increasing trends. *Cancer Causes Control*. 2003;14:791-803.
8. Stiller CA, Desandes E, Danon SE, Izarzugaza I, Ratiu A, Vasileva-Valerianova Z, et al. Cancer incidence and survival in European adolescents (1978-1997). Report from the Automated Childhood Cancer Information System project. *Eur J Cancer*. 2006;42:2006-18.
9. Verdecchia A, Micheli A, Colonna M, Moreno V, Izarzugaza MI, Paci E. A comparative analysis of cancer prevalence in cancer registry areas of France, Italy and Spain. *Ann Oncol*. 2002;13:1128-39.
10. Ferlay J. IARC-Check, de IARC-tolls v2.10 [computer program]. Lyon: IARC; 1999.
11. Organización Panamericana de la Salud, Organización Mundial de la Salud. Clasificación Internacional de Enfermedades para Oncología. 2.^a ed. Ginebra: OMS; 1995.
12. Frome EI, Checkoway H. Use of Poisson regression models in estimating incidence rates and ratios. *Am J Epidemiol*. 1985; 151:309-23.
13. Kim HJ, Fay MP, Feur EJ, Midthune DN. Permutation tests for Joinpoint regression with applications to cancer rates. *Stat Med* 2000;19:335-51 [correction: 2001;20:655].
14. SAS[®] 9.1.3 [computer program]. Cary: SAS Institute Inc.; 2004.
15. Joinpoint Regression Program, Version 3.0. April 2005 [computer program]. Statistical Research and Applications Branch, National Cancer Institute; 2005.
16. Parkin DM, Muir CS, Whelan SL, Gao YT, Ferlay J, Powell JE. Cancer incidence in five continents. Volume VI. Lyon: IARC; 1992. IARC Scientific publications n.º 120.
17. Parkin DM, Whelan SL, Ferlay J, Raymond L, Young L. Cancer incidence in five continents. Volume VII. Lyon: IARC; 1997. IARC Scientific publications n.º 143.
18. Parkin DM, Whelan SL, Ferlay J, Teppo L, Thomas DB. Cancer incidence in five continents. Volume VIII. Lyon: IARC; 2002. IARC Scientific publications n.º 155.
19. Ardanaz E, Moreno C. Registro de cáncer de Navarra. Incidencia y mortalidad por cáncer en Navarra, 1993-1997. Tendencias en los últimos 25 años. *Anales Sis San Navarra*. 2001;24:339-62.
20. Moreno V, González JR, Soler M, Bosch FX, Kogevinas M, Borrás JM, et al. Estimación de la incidencia de cáncer en España: período 1993-1996. *Gac Sanit*. 2001;15:380-8.
21. Izquierdo A, González JR, Moreno V, Galcerán J, Marcosgragera R, Cleries R, et al. Incidencia del cáncer de mama en Cataluña: análisis de la tendencia. *Med Clin (Barc)*. 2006; 126:286-9.
22. Maskarinec G, Zhang Y, Takata Y, Pagano I, Shumay DM, Goodman MT, et al. Trends of breast cancer incidence and risk factor prevalence over 25 years. *Breast Cancer Res Treat*. 2006;98:45-55.
23. Holford TR, Cronin KA, Mariotto AB, Feuer EJ. Changing patterns in breast cancer incidence trends. *J Natl Cancer Inst Monogr*. 2006;36:19-25.
24. Quaglia A, Parodi S, Grosclaude P, Martínez-García C, Coebergh JW, Vercelli M. Differences in the epidemic rise and decrease of prostate cancer among geographical areas in Southern Europe. An analysis of differential trends in incidence and mortality in France, Italy and Spain. *Eur J Cancer*. 2003;39: 654-65.
25. AIRT working group. Italian cancer figures. Report 2006 (I). Incidence, mortality and estimates. *Epidemiol Prev*. 2006;30 Suppl 2:8-30.
26. Ward EM, Thun MJ, Hannan LM, Jemal A. Interpreting cancer trends. *Ann NY Acad Sci*. 2006;1076:29-53.
27. Hayat MJ, Howlader N, Reichman ME, Edwards BK. Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program. *Oncologist*. 2007;12:20-37.
28. Coleman MP, Esteve J, Damiecki P, Arslan A, Renard H. Trends in cancer incidence and mortality. Lyon: 1993. IARC Scientific publications. n.º 121.
29. Janssen-Heijnen ML, Coebergh JW. The changing epidemiology of lung cancer in Europe. *Lung Cancer*. 2003;41:245-58.
30. Fernández E, Schiaffino A, Borrás JM, Shafey O, Villalbi JR, La VC. Prevalence of cigarette smoking by birth cohort among males and females in Spain, 1910-1990. *Eur J Cancer Prev*. 2003;12:57-62.
31. Shafey O, Fernández E, Thun M, Schiaffino A, Dolwick S, Cokinides V. Cigarette advertising and female smoking prevalence in Spain, 1982-1997: case studies in International Tobacco Surveillance. *Cancer*. 2004;100:1744-9.
32. Janssen-Heijnen ML, Coebergh JW. The changing epidemiology of lung cancer in Europe. *Lung Cancer*. 2003;41: 245-58.
33. Stang A, Valiukeviciene S, Aleknaviciene B, Kurtinaitis J. Time trends of incidence, mortality, and relative survival of invasive skin melanoma in Lithuania. *Eur J Cancer*. 2006;42: 660-7.
34. Stang A, Pukkala E, Sankila R, Soderman B, Hakulinen T. Time trend analysis of the skin melanoma incidence of Finland from 1953 through 2003 including 16,414 cases. *Int J Cancer*. 2006;119:380-4.
35. Downing A, Newton-Bishop JA, Forman D. Recent trends in cutaneous malignant melanoma in the Yorkshire region of England; incidence, mortality and survival in relation to stage of disease, 1993-2003. *Br J Cancer*. 2006;95:91-5.
36. de Vries E, Bray FI, Coebergh JW, Parkin DM. Changing epidemiology of malignant cutaneous melanoma in Europe 1953-1997: rising trends in incidence and mortality but recent stabilizations in Western Europe and decreases in Scandinavia. *Int J Cancer*. 2003;107:119-26.
37. De Vries E, Coebergh JW. Cutaneous malignant melanoma in Europe. *Eur J Cancer*. 2004;40:2355-66.
38. Trimboli P, Ulisse S, Graziano FM, Marzullo A, Ruggieri M, Calvanese A, et al. Trend in thyroid carcinoma size, age at diagnosis, and histology in a retrospective study of 500 cases diagnosed over 20 years. *Thyroid*. 2006;16:1151-5.
39. Lundgren CI, Hall P, Ekobom A, Frisell J, Zedenius J, Dickman PW. Incidence and survival of Swedish patients with differentiated thyroid cancer. *Int J Cancer*. 2003;106:569-73.
40. Ward EM, Thun MJ, Hannan LM, Jemal A. Interpreting cancer trends. *Ann NY Acad Sci*. 2006;1076:29-53.
41. Cayuela A, Rodríguez-Domínguez S, López-Campos JL, Vigil E. Age-period-cohort analysis of lung cancer mortality rates in Andalusia, 1975-2004. *Lung Cancer*. 2007;57:261-5.
42. Chirpaz E, Colonna M, Menegoz F, Grosclaude P, Schaffer P, Arveux P, et al. Incidence and mortality trends for prostate cancer in 5 French areas from 1982 to 1996. *Int J Cancer*. 2002;97:372-6.